Evaxion announces completion of ads ratio change

Copenhagen, denmark, jan. 22, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced that the company's previously disclosed change to its ratio of its american depositary shares (“adss”) to its ordinary shares, dkk 1 nominal value (the “ads ratio”), has been made effective. the ratio has changed from one (1) ads representing one (1) ordinary share to a new ads ratio of one (1) ads representing ten (10) ordinary shares (the “ads ratio change”). the ads ratio change became effective on january 22, 2024 (the “effective date”).
EVAX Ratings Summary
EVAX Quant Ranking